Your shopping cart is currently empty

Transdermal Peptide acetate(888486-23-5 free base) (TD 1 (peptide) acetate) is a 11-amino acid peptide, binds toNa+/K+-ATPase beta-subunit (ATP1B1), and mainly interacts with the C-terminus of ATP1B1. Transdermal Peptide can enhance the transdermal delivery of many macromolecules.Transdermal Peptide TD 1 Amide is novel peptide designed to enhance transdermal drug delivery.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $78 | In Stock | In Stock | |
| 5 mg | $171 | In Stock | In Stock | |
| 10 mg | $263 | In Stock | In Stock | |
| 25 mg | $475 | In Stock | In Stock | |
| 50 mg | $695 | In Stock | In Stock | |
| 100 mg | $988 | In Stock | In Stock | |
| 500 mg | $1,980 | - | In Stock |
| Description | Transdermal Peptide acetate(888486-23-5 free base) (TD 1 (peptide) acetate) is a 11-amino acid peptide, binds toNa+/K+-ATPase beta-subunit (ATP1B1), and mainly interacts with the C-terminus of ATP1B1. Transdermal Peptide can enhance the transdermal delivery of many macromolecules.Transdermal Peptide TD 1 Amide is novel peptide designed to enhance transdermal drug delivery. |
| In vitro | In the presence of Transdermal Peptide, because of the specific binding of Transdermal Peptide to ATP1B1, cells will upregulate the level of ATP1B1 to maintain function and structure; as a result, the expression of ATP1B1 increases. However, as time goes on, some Transdermal Peptide molecules may be transported into cells by endocytosis; consequently, the expression of ATP1B1 then decreases. The interaction between Transdermal Peptide and ATP1B1 changes not only the expression of ATP1B1, but also the localization of ATP1B1 and then the structure of the epidermal layer. This interaction can be attenuated by inhibitors or competitors, which would result in the reduced delivery of macromolecular drugs across the skin[1]. |
| Synonyms | Transdermal Peptide Disulfide Acetate (888486-23-5 free base), TD 1 (peptide) acetate |
| Molecular Weight | 1121.2 |
| Formula | C42H68N14O18S2 |
| Smiles | C[C@@H](C(=O)N[C@@H]1CCCC[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](SS(=O)[C@H]2CCCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC1=O)CO)CO)CO)CO)CCCCN)CC3=CN=CN3)C(=O)NCC(=O)O)N.CC(=O)O |
| Relative Density. | no data available |
| Sequence | Ala-Cys-Ser-Ser-Ser-Pro-Ser-Lys-His-Cys-Gly (Cys2-Cys10).CH3CO2H |
| Sequence Short | ACSSSPSKHCG (C2-C10) |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||
| Solubility Information | DMSO: 2.5 mM, Sonication is recommended. | ||||||||||
Solution Preparation Table | |||||||||||
DMSO
| |||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.